Paola Piccini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9174308/publications.pdf

Version: 2024-02-01

72 papers	6,153 citations	101535 36 h-index	102480 66 g-index
73 all docs	73 docs citations	73 times ranked	6332 citing authors

#	Article	IF	Citations
1	Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nature Neuroscience, 1999, 2, 1137-1140.	14.8	663
2	Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Annals of Neurology, 2006, 59, 852-858.	5.3	435
3	Microglial activation in presymptomatic Huntington's disease gene carriers. Brain, 2007, 130, 1759-1766.	7.6	385
4	The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins. Annals of Neurology, 1999, 45, 577-582.	5.3	306
5	Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain, 2011, 134, 969-978.	7.6	283
6	Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinsonâ€™s disease. Scientific Reports, 2017, 7, 1398.	3.3	269
7	Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease. JAMA Neurology, 2014, 71, 83.	9.0	257
8	Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Annals of Neurology, 2000, 48, 689-695.	5.3	246
9	Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain, 2005, 128, 2977-2986.	7.6	241
10	Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study. Neurobiology of Disease, 2010, 40, 216-221.	4.4	213
11	Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinsonâ€™s disease patients. Journal of Clinical Investigation, 2014, 124, 1340-1349.	8.2	202
12	Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study. Human Brain Mapping, 2011, 32, 258-270.	3.6	181
13	Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain, 2008, 131, 2860-2869.	7.6	155
14	Graftâ€induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Movement Disorders, 2011, 26, 1997-2003.	3.9	151
15	Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology, 2012, 79, 523-530.	1.1	150
16	Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Annals of Neurology, 2003, 53, 647-653.	5.3	149
17	Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. Neurobiology of Disease, 2015, 83, 115-121.	4.4	133
18	Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinsonâ€™s disease. Brain, 2016, 139, 2224-2234.	7.6	119

#	Article	IF	Citations
19	Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis. Biological Psychiatry, 2016, 80, 62-72.	1.3	103
20	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinsonâ€™s disease. Brain, 2015, 138, 3003-3015.	7.6	100
21	Altered PDE10A expression detectable early before symptomatic onset in Huntingtonâ€™s disease. Brain, 2015, 138, 3016-3029.	7.6	90
22	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Movement Disorders, 2017, 32, 181-192.	3.9	88
23	In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with ¹⁸F-PBR111 PET. Journal of Nuclear Medicine, 2014, 55, 1112-1118.	5.0	82
24	Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. Brain, 2015, 138, 110-119.	7.6	76
25	11C-Diprenorphine Binding in Huntington's Disease: A Comparison of Region of Interest Analysis with Statistical Parametric Mapping. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 943-949.	4.3	73
26	Serotonin-to-dopamine transporter ratios in Parkinson disease. Neurology, 2016, 86, 1152-1158.	1.1	71
27	Acute and chronic effects of clozapine in essential tremor. Movement Disorders, 1999, 14, 468-472.	3.9	69
28	Functional brain imaging in the differential diagnosis of Parkinson's disease. Lancet Neurology, The, 2004, 3, 284-290.	10.2	66
29	Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: An in vivo [(11)C](R)-PK11195-PET pilot study. Neurobiology of Disease, 2014, 65, 203-210.	4.4	66
30	Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. Movement Disorders, 2016, 31, 1020-1026.	3.9	49
31	Relationship between neuromelanin and dopamine terminals within the Parkinsonâ€™s nigrostriatal system. Brain, 2019, 142, 2023-2036.	7.6	48
32	¹¹Câ€PE2I and ¹⁸Fâ€Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. Movement Disorders, 2018, 33, 117-127.	3.9	45
33	Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease. Nature Reviews Neurology, 2022, 18, 203-220.	10.1	44
34	LEVODOPA-INDUCED DYSKINESIA IN PARKINSON'S: A LONGITUDINAL PET STUDY. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.17-e1.	1.9	43
35	The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. Neurobiology of Aging, 2015, 36, 1736-1742.	3.1	42
36	Morphometric changes in the reward system of Parkinsonâ€™s disease patients with impulse control disorders. Journal of Neurology, 2015, 262, 2653-2661.	3.6	41

#	Article	IF	Citations
37	Single versus multiple impulse control disorders in Parkinsonâ€™s disease: an 11C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. Journal of Neurology, 2015, 262, 1504-1514.	3.6	41
38	New developments of brain imaging for Parkinson's disease and related disorders. Movement Disorders, 2006, 21, 2035-2041.	3.9	34
39	Chronic exposure to dopamine agonists affects the integrity of striatal D 2 receptors in Parkinson's patients. NeuroImage: Clinical, 2017, 16, 455-460.	2.7	33
40	Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review. Neurological Sciences, 2017, 38, 2095-2101.	1.9	30
41	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 301-309.	2.4	30
42	Pallidal dopaminergic denervation and rest tremor in early Parkinson's disease: PPMI cohort analysis. Parkinsonism and Related Disorders, 2018, 51, 101-104.	2.2	22
43	Neurodegenerative movement disorders: the contribution of functional imaging. Current Opinion in Neurology, 2004, 17, 459-466.	3.6	20
44	Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. Movement Disorders, 2017, 32, 235-240.	3.9	18
45	Longitudinal functional connectivity changes related to dopaminergic decline in Parkinsonâ€™s disease. NeuroImage: Clinical, 2020, 28, 102409.	2.7	17
46	PET Imaging in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2015, 4, 287-296.	1.9	16
47	Outcome of cell suspension allografts in a patient with Huntington's disease. Annals of Neurology, 2018, 84, 950-956.	5.3	16
48	Molecular Imaging of Neuroinflammation in Idiopathic Parkinson's Disease. International Review of Neurobiology, 2018, 141, 347-363.	2.0	15
49	Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. Movement Disorders, 2019, 34, 1505-1515.	3.9	15
50	Dyskinesias after transplantation in Parkinson's disease. Lancet Neurology, The, 2002, 1, 472.	10.2	13
51	Problematic Internet use in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 482-487.	2.2	13
52	<scp>Neuromelaninâ€MRI</scp> to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Templateâ€Based Standardized Analysis. Movement Disorders, 2022, 37, 1028-1039.	3.9	12
53	Towards molecular imaging of multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 262-272.	3.0	11
54	Multimodal dopamine transporter (DAT) imaging and magnetic resonance imaging (MRI) to characterise early Parkinson's disease. Parkinsonism and Related Disorders, 2020, 79, 26-33.	2.2	11

#	Article	IF	Citations
55	Clinical utility of DaTscan™ (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes. Degenerative Neurological and Neuromuscular Disease, 2013, 3, 33.	1.3	9
56	Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome. Parkinsonism and Related Disorders, 2015, 21, 1336-1341.	2.2	9
57	Brain Imaging and Impulse Control Disorders in Parkinsonâ€™s Disease. Current Neurology and Neuroscience Reports, 2019, 19, 67.	4.2	8
58	Astrocytes in Parkinson's disease: from preclinical assays to inÂvivo imaging and therapeutic probes. Neurobiology of Aging, 2020, 95, 264-270.	3.1	8
59	Parkinsonâ€™s disease laterality: a 11C-PE2I PET imaging study. Journal of Neurology, 2021, 268, 582-589.	3.6	3
60	SUSCEPTIBILITY WEIGHTED IMAGING TO DETECT NIGRAL IRON ACCUMULATION IN PARKINSON'S DISEASE. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.91-e4.	1.9	2
61	Dissociable effects of age and Parkinsonâ€™s disease on instruction-based learning. Brain Communications, 2021, 3, fcab175.	3.3	2
62	Longitudinal changes in movement-related functional MRI activity in Parkinson's disease patients. Parkinsonism and Related Disorders, 2021, 87, 61-69.	2.2	2
63	J05â€…Legato-hd study: a phase 2 study assessing the efficacy and safety of laquinimod as a treatment for huntington disease. , 2018, , .		2
64	Parkinsonâ€™s Disease Dyskinesias Possibly Relate to Greater Dopamine Transporter Losses in the Putamen Over Time. Journal of Neurology and Experimental Neuroscience, 2019, 5, .	0.1	2
65	Impulse Control Disorders in Parkinsonâ€™s Disease: A Review. Current Psychiatry Reviews, 2012, 8, 235-246.	0.9	1
66	Restorative Strategies in Movement Disorders: the Contribution of Imaging. Current Neurology and Neuroscience Reports, 2017, 17, 98.	4.2	1
67	PET Imaging in Multiple Sclerosis: Focus on the Translocator Protein. , 2014, , 757-773.		1
68	Dopamine Transporter Density in Parkinson's Disease Does Not Relate to the Development of Levodopa-Induced Dyskinesias. , 2019, 3, 10000.		1
69	SEROTONIN-TO-DOPAMINE TRANSPORTER RATIOS IN THE STRIATUM OF PATIENTS WITH PARKINSON'S DISEASE: IMPACT ON LEVODOPAâ€“INDUCED DYSKINESIAS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.96-e4.	1.9	0
70	PO105â€…Levodopa-induced dyskinesias in parkinsonâ€™s: imaging of striatal dat density over time. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A39.2-A39.	1.9	0
71	PO088â€…Nigral iron susceptibility in parkinsonâ€™s disease: a longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A34.4-A35.	1.9	0
72	Cell-Based Therapies. , 2011, , 173-180.		0